Dr. Catherine Shu, MD
Claim this profileColumbia University
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
8 reported clinical trials
14 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
EGFR positive
Stage IV
Stage III
2Lung Cancer
EGFR positive
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Catherine Shu, MD is currently running
Rituximab or Tocilizumab
for Immune-Related Side Effects
The purpose of this study is to examine how effective rituximab or tocilizumab are in treating side effects for people who are receiving immunotherapy treatment requiring prolonged steroid use. Immune-related side effects are caused by the activation of the immune system. Because rituximab and tocilizumab have been shown to effectively in treating other diseased that involve immune system activation, this study seeks to evaluate how effective they will be in treating immune-related side effects in people receiving immunotherapy treatment for cancer.
Recruiting1 award Phase 211 criteria
H002
for Non-Small Cell Lung Cancer
This is a phase I/IIa, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of H002 when given orally in patients with active EGFR mutation locally advanced or metastatic non-small cell lung cancer (NSCLC). The study will contain two parts: Part A is dose escalation phase (i.e., Phase I) and Part B is dose expansion phase (i.e., Phase IIa).
Recruiting1 award Phase 1 & 212 criteria
More about Catherine Shu, MD
Clinical Trial Related5 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Catherine Shu, MD has experience with
- Durvalumab
- Pembrolizumab
- H002
- Tremelimumab
- Osimertinib
- Ramucirumab
Breakdown of trials Catherine Shu, MD has run
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Epidermal Growth Factor Receptor Mutations
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Catherine Shu, MD specialize in?
Catherine Shu, MD focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved EGFR positive patients, or patients who are Stage IV.
Is Catherine Shu, MD currently recruiting for clinical trials?
Yes, Catherine Shu, MD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Catherine Shu, MD has studied deeply?
Yes, Catherine Shu, MD has studied treatments such as Durvalumab, Pembrolizumab, H002.
What is the best way to schedule an appointment with Catherine Shu, MD?
Apply for one of the trials that Catherine Shu, MD is conducting.
What is the office address of Catherine Shu, MD?
The office of Catherine Shu, MD is located at: Columbia University, New York, New York 10032 United States. This is the address for their practice at the Columbia University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.